Nutriband and Kindeva Strengthen Partnership for Fentanyl Patch
Nutriband and Kindeva Enhance Collaboration for Aversa™ Fentanyl Patch
Nutriband and Kindeva have come together for exclusive product development, sharing costs and benefits from milestone payments.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has recently formalized its partnership with Kindeva Drug Delivery to enhance the Aversa™ Fentanyl project. This collaboration focuses on merging Nutriband’s proprietary Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved transdermal fentanyl delivery system. The agreement reflects a strong commitment from both companies to work collaboratively on this innovative product.
Under this revised agreement, both companies will share development costs and commit to long-term milestones. This partnership aims to address the critical issue of opioid misuse by developing a product that not only provides pain relief but also minimizes the risk of abuse.
The Aversa™ Abuse-Deterrent Technology Explained
Nutriband’s Aversa™ technology is at the forefront of pharmaceutical innovation, specifically designed to reduce the potential for drug abuse. By incorporating aversive agents into transdermal patches, this technology plays a significant role in preventing the misuse, diversion, and accidental exposure of medications, particularly opioids and stimulants.
This unique technology works by employing taste aversion, which can deter oral abuse of transdermal patches, effectively decreasing the likelihood of drug misuse and accidental exposure. The solution is equipped with an extensive international patent portfolio, affirming its protection in key markets such as the United States, Europe, Japan, and more.
Potential Market Impact of Aversa™ Fentanyl
The introduction of Aversa Fentanyl is anticipated to significantly impact the opioid market. With projections estimating peak annual U.S. sales between $80 million to $200 million, this innovative patch represents a pioneering approach in addressing the challenges posed by traditional fentanyl patches.
By focusing on safety and accessibility, Aversa™ technology aims to uphold the balance required for patients needing pain management while safeguarding against the dangers of opioid misuse. As the opioid crisis continues to be a pressing concern, Nutriband's advancements present a hopeful avenue for more responsible drug products.
About Nutriband Inc.
Nutriband Inc. is dedicated to the development of transdermal pharmaceutical products, leveraging innovative technologies like Aversa™ to ensure safe usage of medications with abuse potential. By combining state-of-the-art technology with patient-focused solutions, Nutriband strives to redefine how medications are delivered and consumed.
Company Vision
Nutriband remains committed to constructing a future where safety is prioritized alongside patient needs. By focusing on cutting-edge research and partnerships, the company is set to lead the charge towards safer pharmaceutical solutions.
Achievements and Future Goals
The journey of Nutriband is underscored by milestones in technology development and strategic collaborations. Embracing the responsibility of addressing public health concerns, Nutriband envisions a future enriched with innovation in drug delivery systems.
Frequently Asked Questions
What is Aversa™ Fentanyl?
Aversa™ Fentanyl is an innovative abuse-deterrent transdermal patch designed to provide pain relief while minimizing the potential for misuse and accidental exposure.
What technology does Nutriband use for Aversa™?
Nutriband utilizes its proprietary Aversa™ technology, which incorporates aversive agents that discourage oral abuse of the patch, thus enhancing safety.
What is the market potential for Aversa Fentanyl?
Estimates suggest that Aversa Fentanyl could reach peak U.S. sales of $80 million to $200 million, addressing significant market needs.
Who partners with Nutriband for this development?
Kindeva Drug Delivery is the exclusive partner working collaboratively with Nutriband to develop the Aversa™ Fentanyl patch.
How can I contact Nutriband Inc.?
You can reach Nutriband Inc. by phone at 407-377-6695 or via email at info@nutriband.com.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
